Viatris VTRS Greater China — Net Sales
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's greater china — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Viatris's greater china — net sales?
- Viatris (VTRS) reported greater china — net sales of $680.1M in Q1 2026.
- How has Viatris's greater china — net sales changed year-over-year?
- Viatris's greater china — net sales increased by 22.4% year-over-year, from $555.5M to $680.1M.
- What is the long-term trend for Viatris's greater china — net sales?
- Over 4 years (2021 to 2025), Viatris's greater china — net sales has grown at a 1.3% compound annual growth rate (CAGR), from $2.21B to $2.33B.
- What does greater china — net sales mean?
- Represents the total revenue generated from the sale of pharmaceutical products and services within the Greater China geographic region. This metric reflects the market demand and commercial success of the company's portfolio in this specific territory.